J9

• Background :

  J9, in combination with dexamethasone inhibits cell growth in T-cell acute lymphoblastic leukemia (T-ALL) through the upregulation of the glucocorticoid receptor. Patients can develop glucocorticoid resistance rendering the treatment ineffective. J9 and its mechanism of action provides a useful strategy for overcoming the resistance. The EC50 of J9 in combination with dexamethasone is 28 uM. J9 alone was less toxic.

• Description :

  Glucocorticoid resistance inhibitor

• Product Name Alternative :

  4-cyclopropyl-5- (pyridin-4-yl) pyrimidin-2-amine

• UNSPSC :

  41116105

• Type :

  Inhibitor

• Source :

  Synthetic

• Field of Research :

  Cancer | Cell Signaling | Epigenetics and Nuclear Signaling

• Purity :

  99.9%

• Weight :

  0.01

• Format :

  White Solid

• Solubility :

  Soluble in CDCI3

• Molecular Formula :

  C12H12N4

• Molecular Weight :

  212.26

• Precautions :

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations :

  1. Cantley A.M., et al. (2014) ACS Medicinal Chemistry Letters 5.7: 754-759.